CN117771345A - Wac在制备预防和/或治疗骨质疏松症的药剂中的应用 - Google Patents
Wac在制备预防和/或治疗骨质疏松症的药剂中的应用 Download PDFInfo
- Publication number
- CN117771345A CN117771345A CN202311798016.7A CN202311798016A CN117771345A CN 117771345 A CN117771345 A CN 117771345A CN 202311798016 A CN202311798016 A CN 202311798016A CN 117771345 A CN117771345 A CN 117771345A
- Authority
- CN
- China
- Prior art keywords
- wac
- protein
- mscs
- formulation
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 101000771778 Homo sapiens WW domain-containing adapter protein with coiled-coil Proteins 0.000 claims abstract description 108
- 102100029472 WW domain-containing adapter protein with coiled-coil Human genes 0.000 claims abstract description 108
- 230000009818 osteogenic differentiation Effects 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 claims abstract description 31
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 claims abstract description 31
- 230000004900 autophagic degradation Effects 0.000 claims abstract description 20
- 230000015556 catabolic process Effects 0.000 claims abstract description 11
- 238000006731 degradation reaction Methods 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims abstract 2
- 230000002438 mitochondrial effect Effects 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000010798 ubiquitination Methods 0.000 claims description 6
- 230000034512 ubiquitination Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 101150099050 WAC gene Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000013605 shuttle vector Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 53
- 230000001105 regulatory effect Effects 0.000 abstract description 14
- 230000001276 controlling effect Effects 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 210000003470 mitochondria Anatomy 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 230000037182 bone density Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 61
- 238000010186 staining Methods 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 238000001262 western blot Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 16
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 16
- 238000003197 gene knockdown Methods 0.000 description 15
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 13
- 241000713666 Lentivirus Species 0.000 description 11
- 210000000689 upper leg Anatomy 0.000 description 9
- 230000009456 molecular mechanism Effects 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000751 protein extraction Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 210000004957 autophagosome Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 3
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 3
- 101100190541 Caenorhabditis elegans pink-1 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 239000012083 RIPA buffer Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002331 protein detection Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 description 2
- 101000599779 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 2 Proteins 0.000 description 2
- 101000645277 Homo sapiens Mitochondrial import inner membrane translocase subunit Tim23 Proteins 0.000 description 2
- 101000798951 Homo sapiens Mitochondrial import receptor subunit TOM20 homolog Proteins 0.000 description 2
- 102100037919 Insulin-like growth factor 2 mRNA-binding protein 2 Human genes 0.000 description 2
- 102100026255 Mitochondrial import inner membrane translocase subunit Tim23 Human genes 0.000 description 2
- 102100034007 Mitochondrial import receptor subunit TOM20 homolog Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000002624 Sp7 Transcription Factor Human genes 0.000 description 2
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100021740 E3 ubiquitin-protein ligase BRE1A Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000896083 Homo sapiens E3 ubiquitin-protein ligase BRE1A Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940053838 glucose 1000 mg Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- -1 polyoxymethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002943 spectrophotometric absorbance Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于医药技术领域,公开了一种WAC在制备预防和/或治疗骨质疏松症的药剂中的应用。本发明提供了一种用于预防和/或治疗骨质疏松症的蛋白药物WAC蛋白。本发明研究发现WAC通过调控PINK1的降解,调控线粒体自噬水平,最后影响MSCs的成骨分化能力,发现WAC在维持骨形成以及通过提高骨密度、骨体积分数、骨小梁数目、骨小梁厚度可治疗骨质疏松,为临床上骨质疏松症的预防或治疗提供新的方向和方法。
Description
在技术领域
本发明涉及医药技术领域,具体涉及一种WAC在制备预防和/或治疗骨质疏松症的药剂中的应用。
背景技术
骨质疏松是一种常见的骨骼疾病,其主要特征是骨密度下降,骨组织结构变得脆弱,容易骨折。随着人口寿命增加及人口老龄化程度的加重,骨质疏松导致的各种骨折、疼痛、活动障碍给我国带来巨大的医疗系统负担,因此,针对骨质疏松的防治对个人和社会都至关重要。骨质疏松发生发展过程涉及间充质干细胞(MSCs)的成骨分化功能障碍,因此探究MSCs成骨分化分子机制,可为骨质疏松的诊疗提供新的方向。
线粒体是真核细胞进行生物氧化和能量转换的重要场所。线粒体自噬(Mitophagy)通过受体介导的机制靶向受损线粒体的降解,在机体正常情况下,细胞可以通过清除受损线粒体,维持细胞的正常生理功能。当机体受到氧化应激、内质网应激、缺血缺氧、营养物质缺乏等损伤时,也会促进线粒体自噬。而异常的线粒体自噬则会导致多种疾病的发生发展,包括神经退行性疾病,心血管疾病,肌肉疾病,炎症和癌症等。
发明内容
本发明的目的在于克服现有技术的不足之处而提供一种WAC在制备预防和/或治疗骨质疏松症的药剂中的应用。
为实现上述目的,本发明采取的技术方案如下:
第一方面,本发明提供了一种用于预防和/或治疗骨质疏松症的蛋白药物,所述蛋白药物为WAC蛋白。
本发明研究发现WAC通过调控PINK1的降解,调控线粒体自噬水平,最后影响MSCs的成骨分化能力,发现WAC在维持骨形成以及通过提高骨密度、骨体积分数、骨小梁数目、骨小梁厚度可治疗骨质疏松,为临床上骨质疏松症的预防或治疗提供新的方向和方法。
第二方面,本发明提供了一种用于预防和/或治疗骨质疏松症的制剂,所述制剂包括WAC蛋白和和至少一种药学上可接受的载体和/或辅料。
作为本发明所述的制剂的优选实施方式,所述制剂为口服制剂或注射剂。
进一步的,所述注射剂为溶液、悬浮液、乳剂或者无菌粉末形式的制剂。
第三方面,本发明提供了一种过表达WAC的腺病毒,包括穿梭载体和WAC基因序列。
第四方面,本发明将所述蛋白药物、所述制剂、所述腺病毒在制备预防和/或治疗骨质疏松症的药剂中应用。
作为本发明所述的应用的优选实施方式,可单独给药或联合治疗。
第五方面,本发明将所述蛋白药物、所述制剂、所述腺病毒在制备调控MSCs成骨分化的制剂中应用。
第六方面,本发明将所述蛋白药物、所述制剂、所述腺病毒在制备调控PINK1的泛素化降解调控线粒体自噬的制剂中应用。
与现有技术相比,本发明的有益效果为:
本发明通过探究WAC对MSCs成骨分化能力的调控作用,提供了一种新的调控线粒体自噬的分子机制。本发明阐明了WAC通过调控PINK1的降解,调控线粒体自噬水平,最后影响MSCs的成骨分化能力。本发明通过探究WAC对于维持骨量、治疗骨质疏松的作用,提供了WAC在维持骨形成以及治疗骨质疏松方面的应用(如通过提高骨密度、骨体积分数、骨小梁数目、骨小梁厚度预防和治疗骨质疏松症),可补充WAC以预防和治疗骨质疏松症,为临床上骨质疏松症的治疗提供新的方向和方法。
附图说明
图1为WAC调控MSCs成骨分化的作用;
图中,(A)使用Si-RNA和慢病毒在MSCs细胞系中敲低/过表达WAC后,通过ARS、ALP染色检测MSCs成骨分化能力;(B)通过使用Si-RNA和慢病毒在MSCs细胞系中敲低/过表达WAC后,通过Western blotting检测WAC及MSCs成骨分化相关标志物(RUNX2、Osterix、OCN)的蛋白质水平。
图2为WAC调控MSCs成骨分化的分子机制;
图中,(A)使用Si-RNA和慢病毒在MSCs细胞系中敲低/过表达WAC后,通过Westernblotting检测WAC及线粒体自噬水平相关蛋白(PINK1、P62、VDAC、TIMM23、LC3B)蛋白质水平。(B)使用Si-RNA在MSCs细胞系中敲低WAC后,通过电镜观察细胞内线粒体形态及自噬小体的数量。(C)使用Si-RNA和慢病毒在MSCs细胞系中敲低/过表达WAC后,通过共聚焦激光显微镜,检测细胞内LC3B的荧光强度。(D)使用Si-RNA在MSCs细胞系中敲低WAC后,加入线粒体自噬激动剂CCCP,随后通过ARS、ALP染色检测MSCs的成骨分化能力,通过Western blotting检测线粒体自噬水平。
图3为WAC调控PINK1的分子机制;
图中,(A)通过Co-IP分别提取MSCs中与PINK1、WAC结合的蛋白,使用Westernblotting检测MSCs中WAC和PINK1的相互作用。(B)使用Si-RNA在MSCs细胞系中敲低WAC后,使用CHX抑制蛋白合成,检测PINK1的降解速率变化。(C)使用Si-RNA在MSCs细胞系中敲低WAC后,分别加入CQ和Mg132,通过Western blotting检测PINK1的蛋白水平,检测PINK1的降解方式。(D)使用Si-RNA在MSCs细胞系中敲低WAC后并加入Mg132,随后通过CO-IP分离PINK1,通过Western blotting检测泛素化水平的变化。
图4为为了检测WAC对于维持骨量和治疗骨质疏松的作用;
图中,(A)Micro-CT扫描分析WAC间充质干细胞特异性敲除小鼠股骨远端;(B)WAC间充质干细胞特异性敲除小鼠股骨骨体积分数(Bone Volume/Total Volume),骨表面积/体积(Bone Surface Area/Bone Volume),骨小梁厚度(Trabecular Thickness),骨小梁数量(Trabecular Number),骨小梁间距(Trabecular Spacing),和骨小梁模式因子(Trabecular Pattern Factor)指标的检测。(C)Micro-CT扫描分析卵巢切除(OVX)小鼠以及注射慢病毒过表达WAC的OVX小鼠的股骨远端。(D)OVX小鼠以及注射慢病毒过表达WAC和PINK1的OVX小鼠股骨骨体积分数(Bone Volume/Total Volume),骨表面积/体积(BoneSurface Area/Bone Volume),骨小梁厚度(Trabecular Thickness),骨小梁数量(Trabecular Number),骨小梁间距(Trabecular Spacing),和骨小梁模式因子(Trabecular Pattern Factor)指标的检测。
具体实施方式
为更好地说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。本领域技术人员应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明。
实施例中所用的试验方法如无特殊说明,均为常规方法;所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
WAC(WW domain containing adaptor with coiled-coil;NG_046603)定位于细胞核及高尔基体内,其特点在于通过N端的WW区域及C端卷曲螺旋区域实现蛋白质-蛋白质作用。较为明确的是WAC作为RNF20/40的结合伴侣,协助调控H2B的泛素化,进而调节转录。现有研究主要提示WAC与癫痫、智力障碍等中枢神经系统疾病相关,但WAC与骨科相关疾病尤其是骨质疏松缺乏认识。
本发明实施例所涉及的相关实验方法如下:
(1)MSCs诱导成骨分化
将MSCs以0.8×105个/孔的密度分别接种于12孔板的培养液中。12小时后,当细胞粘附在孔中时,将MSCs的培养基换成成骨分化培养基,其中包括DMEM(葡萄糖1000mg/L)、10%胎牛血清、100IU/mL青霉素、100IU/mL链霉素、0.1μM地塞米松、10mMβ-磷酸甘油和50μM抗坏血酸。培养基每3天更换一次,共诱导12天。
(2)构建基因敲低模型
利用SiRNA介导转染细胞系构建技术,在间充质干细胞(MSCs)系中敲低WAC,获得WAC敲低的MSCs细胞系。
靶向WAC SiRNA和阴性对照购自IGEbio(中国广州)。具体序列如下:
Si1-WAC:CCAGUUACUCUCCACAAGATT;
Si2-WAC:GUCGAACAGAAGUUUCACATT;
Si-Control:UUCUCCGAACGUGUCACGUTT。
当细胞达到60%-80%的融合度时,用Opti-MEM还原血清培养基、LipofectamineTMRNAiMAX(Invitrogen公司)和siRNA(每1.8×106个细胞1OD)按照生产商的说明转染间充质干细胞。转染5小时后,移除转染培养基。48小时后检测基因敲除效率并进行后续实验,在成骨诱导的第6天再次使用siRNA敲除目标基因。
(3)构建基因过表达模型
慢病毒、包括载体对照和WAC过表达腺病毒,均由上海欧必欧科技有限公司设计和合成。间充质干细胞与含慢病毒(MOI=30)、5μg/mL polybrene和完全培养基的预混合培养基孵育24h,然后进行后续实验。
(4)茜素红(ARS)染色
将MSCs浸泡在4%多聚甲醛溶液中固定30分钟。固定后,用1%的茜素红S(ARS)溶液(pH 4.3)在室温下染色15分钟。为了消除任何非特异性染色,染色细胞至少要经过三次磷酸盐缓冲盐水(PBS)的严格清洗。随后,在显微镜下检查染色细胞,并通过拍照进行捕捉。为了对ARS染色进行定量评估,在室温下用10%的一水十六烷基氯化吡啶溶液(Sigma-Aldrich)对细胞进行浸泡1小时。浸泡后,将200μL所得溶液转移到96孔板中,在562纳米波长处测量分光光度吸光度。
(5)碱性磷酸酶(ALP)染色和活性测定
为了进行ALP染色,固定在甲醛溶液中,并按照生产商的说明使用BCIP/NBT碱性磷酸酶试剂盒(贝奥特姆生物技术研究所)进行染色。对染色细胞进行拍照。
ALP活性检测使用ALP活性试剂盒(南京健成生物技术有限公司)。简言之,使用含有蛋白酶和磷酸酶抑制剂的RIPA缓冲液(中国生物技术研究所)裂解间充质干细胞。裂解液在4℃、14,000rpm转速下离心30分钟,上清液与反应缓冲液在37℃温育15分钟。加入终止液后,在405纳米波长处测量吸光度。使用Pierce bicinchoninic acid(BCA)蛋白检测试剂盒(Thermo Fisher Scientific)检测总蛋白浓度。实验结束时,将ALP活性归一化为总蛋白质含量,并以每克蛋白质每15分钟的单位(U/gpro/15分钟)进行报告。
(6)蛋白质提取和蛋白免疫印迹(Western blotting)
用含1%磷酸酶抑制剂和蛋白酶抑制剂的RIPA缓冲液裂解细胞,冰浴30分钟。收集细胞裂解液,然后在4℃下离心14,000rpm 30分钟。收集蛋白上清液后,使用BCA蛋白检测试剂盒测量并量化蛋白浓度。等量蛋白质与SDS-PAGE缓冲液混合,通过SDS聚丙烯酰胺凝胶电泳分离,并转移到聚偏氟乙烯膜上。然后用一抗在4℃下孵育过夜。之后,用三相缓冲盐水-吐温(TBST)洗膜3次以消除非特异性结合,并与HRP结合的二抗在室温下孵育1小时。洗膜3次后,使用化学发光HRP底物检测目标蛋白条带,并使用ImageJ软件进行密度分析。
(7)透射电子显微镜分析
收获MSCs,离心,然后用4%甲醛和2.5%戊二醛在0.1M PB(pH 7.4)中固定过夜。将样本预埋在琼脂糖中后,在室温下用0.1M磷酸盐缓冲液(pH 7.0)中的1%OsO4后固定2小时。样品在室温下用浓度递增的乙醇(30%、50%、70%、80%、95%和100%)脱水20分钟,最后用两种丙酮溶液孵育15分钟。经树脂渗透、聚合、超薄切片和染色后,用TEM观察间充质干细胞的超微结构并拍照。
(8)免疫荧光
MSCs接种在无菌玻璃盖玻片上。当细胞达到适当的汇合度时,吸出生长培养基。细胞用PBS冲洗3次,然后在4%多聚甲醛中固定30分钟。为使细胞通透,室温下加入0.1%Triton X-100 15分钟,并用5%正常山羊血清孵育细胞30分钟。加入LC3B和TOM20一抗,4℃孵育细胞过夜。用PBS冲洗细胞3次后,加入抗兔IgG和抗鼠IgG,室温下再孵育1小时。用4′,6-二脒基-2-苯基吲哚(DAPI)对细胞核进行反染色。然后在激光扫描共聚焦显微镜下观察样品,波长分别为488nm(绿色,LC3B)、555nm(红色,TOM20)和405nm(蓝色,DAPI)。使用LSM5Exciter共聚焦成像系统(卡尔蔡司)获取图像。
(9)免疫共沉淀(Co-IP)
快速收获MSCs细胞并在冰上匀浆,加入改良的RIPA缓冲液,其中含有50mM Tris-HCl(pH 7.5)、150mM NaCl、0.1%(体积分数)Triton X-100、0.5%(重量/体积)脱氧胆酸钠、0.1%(重量/体积)SDS、1mM EDTA、50mM N-乙基马来酰亚胺、1mM NaF、1mM Na3VO4、1mMPMSF和1μg/mL aprotinin、leupeptin和pepstatin。将细胞提取物(约200μg总蛋白)与抗-PINK1、抗-WAC或其IgG对照的抗体在4℃下孵育3小时。然后加入蛋白-G琼脂糖珠,混合物在4℃孵育过夜。收集琼脂糖珠,洗涤并重悬于90μL样品缓冲液中,缓冲液含有50mM Tris-HCl,pH 7.6,2%(重量/体积)SDS,10%(体积/体积)甘油,10mM DTT和0.2%溴酚蓝。然后将样品煮沸10分钟。蛋白免疫印迹步骤如上所述。
(10)构建WAC间充质干细胞特异性敲除小鼠(Prx1-cre;WACfl/fl CKO)
C57BL/6Prx1-cre小鼠购自杰克逊实验室。C57BL/6WACfl/fl转基因小鼠购自GemPharmatech公司,用于构建Prx1-cre;WACfl/fl CKO小鼠。
以下PCR引物用于WACfl/fl的基因分型:
5'臂引物正向:TCCATCTCTTCCAACAAGTTGAGT;
5'臂引物反向:CACATCTGACTTCAAAGTTCTTGC。
野生型小鼠只能检测到185-bp DNA条带,而同源WACfl/fl小鼠只能检测到248-bpDNA条带。杂合子小鼠(WACfl/-)将检测到185-bp和248-bp PCR DNA条带。
Cre序列的PCR引物用于检测Prx1-Cre小鼠中的Prx1-cre转基因:
Prx1-cre正向引物:GCTCTGATGTTGGCAAAGGGGT;
Prx1-cre反向引物:AACATCTTCAGGTTCTGCGGG。
待小鼠16周龄时,处死小鼠并留取股骨标本。
(11)小鼠绝经后骨质疏松症模型(OVX)的构建和处理
8周龄雌性小鼠接受双侧卵巢切除术,其他小鼠接受假手术。卵巢切除7天后,通过尾静脉注射rAAV9-WAC及rAAV9-PINK1。手术两个月后,小鼠被处死以并留取股骨标本进行后续实验。
(12)显微CT(Micro-CT)扫描
用4%聚甲醛固定小鼠股骨1天。使用Micro-CT系统(西门子)进行扫描和分析。简而言之,在360个旋转步骤中的每个步骤中,以80kV的电压、500lA的电流、8.82lm的有效像素尺寸和1500ms的曝光时间拍摄图像,以检查骨骼。使用Micro-CT分析软件重建图像切片,生成二维和三维结构。通过测定骨体积分数(Bone Volume/Total Volume),骨表面积/体积(Bone Surface Area/Bone Volume),骨小梁厚度(Trabecular Thickness),骨小梁数量(Trabecular Number),骨小梁间距(Trabecular Spacing),和骨小梁模式因子(Trabecular Pattern Factor)分析骨量。
实施例1:确定WAC对MSCs成骨分化的影响
为了检测WAC调控MSCs成骨分化的作用,对细胞系进行成骨分化诱导,随后在诱导的第12天进行染色和蛋白提取,通过ARS染色、ALP染色、Western blotting(蛋白免疫印迹)对其表型进行观察,并分析MSCs成骨分化能力的变化。具体为:
使用Si-RNA和慢病毒分别在MSCs细胞中敲低/过表达WAC,通过成骨分化培养基诱导成骨分化12天,随后通过ARS染色、ALP染色分别检测成骨分化水平,可以看到敲低WAC并予以ARS染色后,视野下钙结节减少,染色变浅,ARS定量分光度降低,予以ALP染色同样发现染色变浅,ALP活性降低,均提示敲减WAC后MSCs成骨分化能力下降。而过表达WAC后则有相反的结果,ARS染色后,视野中钙结节增多,染色加深,ARS定量分光度升高。ALP染色后观测到染色变深,ALP活性升高,提示过表达WAC后,MSCs成骨分化能力上升(图1A)。随后我们分别从细胞裂解物中提取蛋白质,使用Western blotting检测WAC和成骨相关标志物(RUNX2、Osterix、OCN)的蛋白质水平,同样提示WAC对MSCs成骨分化能力的促进作用(图1B)。
实施例2:探究WAC调控MSCs成骨分化能力的机制
为了检测WAC调控MSCs成骨分化的分子机制,通过对实施例1中的细胞系进行蛋白提取后,通过Western blotting检测线粒体自噬相关蛋白水平。通过电镜观察细胞内线粒体等细胞器的形态及自噬小体的数量,来分析线粒体自噬水平。具体如下:
使用Si-RNA和慢病毒分别在MSCs细胞中敲低/过表达WAC并诱导成骨分化,随后提取蛋白质,并使用Western blotting检测WAC和线粒体自噬相关标志物(PINK1、P62、VDAC、TIMM23、LC3B)的蛋白质水平,敲低WAC后,线粒体自噬相关标志物蛋白水平变化提示线粒体自噬水平的下降,过表达WAC后则提示线粒体自噬水平的上升(图2A)。使用Si-RNA敲低WAC后,收集并固定细胞,予以透射电子显微镜分析,观察对照组MSCs中线粒体形态变圆,嵴变的模糊不清,周围可看到较多双层膜结构包含细胞器的自噬小体。与对照组相比,敲低WAC后,MSCs中线粒体形态为长条状,嵴结构清楚,更接近正常的线粒体形态,周围的自噬小体数量较少(图2B)。使用Si-RNA和慢病毒分别在MSCs细胞中敲低/过表达WAC并诱导成骨分化后,予以免疫荧光,可观察到,LC3B与TOM20共定位,并且与对照组相比,敲低WAC后,LC3B荧光强度降低。过表达WAC后,LC3B荧光强度升高(图2C)。为进一步验证WAC通过影响线粒体自噬水平影响MSCs成骨分化,在使用Si-RNA敲低WAC时,同时使用不同浓度的线粒体自噬诱导剂(CCCP)刺激MSCs,随后使用ARS染色、ALP染色评估成骨分化能力,发现CCCP可以逆转敲低WAC对于MSCs成骨分化的损害。提取蛋白,使用Western blotting再次验证线粒体自噬水平。发现CCCP同样逆转了敲低WAC对于MSCs线粒体自噬水平的损害(图2D)。
实施例3:探究WAC调控PINK1的分子机制
为了检测WAC调控PINK1的分子机制,使用Co-IP分别从MSCs中分离出与PINK1和WAC结合的蛋白,并使用Western blotting检测PINK1和WAC的蛋白水平,发现,WAC与PINK1相互结合(图3A)。
为了检测WAC是否影响了PINK1的降解,先试用Si-RNA敲低WAC,并使用核糖体抑制剂(CHX)抑制蛋白合成,在不同时间点提取蛋白,随后使用Western blotting检测PINK1的蛋白水平下降速率,结果提示敲低WAC后,PINK1蛋白水平下降更快,提示敲低WAC使得PINK1降解更快(图3B)。
蛋白质主要通过蛋白酶体途径或者溶酶体途径降解,为了检测PINK1是通过何种途径,在敲低WAC后使用Mg132和CQ分别抑制蛋白酶体和溶酶体活性,随后提取蛋白并使用Western blotting检测PINK1蛋白水平,结果提示Mg132可以逆转敲低WAC对于PINK1蛋白水平的损害,即PINK1通过泛素-蛋白酶体途径降解(图3C)。随后在敲低WAC后使用Co-IP分离PINK1蛋白,并使用Western blotting检测PINK1的泛素化水平,发现敲低WAC后,PINK1蛋白的泛素化水平升高(图3D)。
实施例4:探究WAC对于维持骨量、治疗骨质疏松的作用
为了检测WAC对于维持骨量和治疗骨质疏松的作用,通过构建间充质干细胞特异性敲除小鼠模型以及向绝经性骨质疏松小鼠模型注射WAC和PINK1的过表达腺病毒,通过micro-CT分析骨量的变化。具体如下:
构建了Prx1-cre;WACfl/fl CKO,并在小鼠12周龄时收取小鼠股骨标本,随后予以Micro-CT扫描,显示股骨远端矢状位和横断面截图,并通过三维重建骨小梁结构。结果显示与对照组相比,Prx1-cre;WACfl/fl CKO小鼠股骨中骨小梁体积和数量更少(图4A)。予以分析骨量提示Prx1-cre;WACfl/fl CKO小鼠股骨骨量更低(图4B)。随后我们构建了OVX小鼠,并通过尾静脉注射rAAV9-WAC和rAAV9-WAC,特异性在骨组织中过表达WAC和PINK1,随后予以Micro-CT扫描,结果显示与对照组相比,OVX小鼠股骨中骨小梁体积和数量更少,予以注射rAAV9-WAC、rAAV9-PINK1后,股骨内骨小梁体积和数量较单纯OVX小鼠升高(图4C)。予以分析骨量同样提示OVX小鼠骨量降低,注射rAAV9-WAC和rAAV9-PINK1可部分逆转OVX小鼠的骨量降低(图4D)。
本发明通过探究WAC对MSCs成骨分化能力的调控作用,提供了一种新的调控线粒体自噬的分子机制。阐明了WAC通过调控PINK1的降解,调控线粒体自噬水平,最后影响MSCs的成骨分化能力。并通过探究WAC对于维持骨量、治疗骨质疏松的作用,提供了WAC在维持骨形成以及治疗骨质疏松方面的应用(如通过提高骨密度、骨体积分数、骨小梁数目、骨小梁厚度预防和治疗骨质疏松症),可补充WAC以预防和治疗骨质疏松症,为临床上骨质疏松症的治疗提供新的方向和方法。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (9)
1.一种用于预防和/或治疗骨质疏松症的蛋白药物,其特征在于,所述蛋白药物为WAC蛋白。
2.一种用于预防和/或治疗骨质疏松症的制剂,其特征在于,所述制剂包括WAC蛋白和和至少一种药学上可接受的载体和/或辅料。
3.根据权利要求2所述的制剂,其特征在于,所述制剂为口服制剂或注射剂。
4.根据权利要求3所述的制剂,其特征在于,所述注射剂为溶液、悬浮液、乳剂或者无菌粉末形式的制剂。
5.一种过表达WAC的腺病毒,其特征在于,包括穿梭载体和WAC基因序列。
6.权利要求1所述蛋白药物、权利要求2-4任一项所述制剂、权利要求5所述腺病毒在制备预防和/或治疗骨质疏松症的药剂中的应用。
7.根据权利要求6所述的应用,其特征在于,可单独给药或联合治疗。
8.权利要求1所述蛋白药物、权利要求2-4任一项所述制剂、权利要求5所述腺病毒在制备调控MSCs成骨分化的制剂中的应用。
9.权利要求1所述蛋白药物、权利要求2-4任一项所述制剂、权利要求5所述腺病毒在制备调控PINK1的泛素化降解调控线粒体自噬的制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311798016.7A CN117771345A (zh) | 2023-12-25 | 2023-12-25 | Wac在制备预防和/或治疗骨质疏松症的药剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311798016.7A CN117771345A (zh) | 2023-12-25 | 2023-12-25 | Wac在制备预防和/或治疗骨质疏松症的药剂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117771345A true CN117771345A (zh) | 2024-03-29 |
Family
ID=90388524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311798016.7A Pending CN117771345A (zh) | 2023-12-25 | 2023-12-25 | Wac在制备预防和/或治疗骨质疏松症的药剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117771345A (zh) |
-
2023
- 2023-12-25 CN CN202311798016.7A patent/CN117771345A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ho et al. | Egr-1 deficiency protects from renal inflammation and fibrosis | |
Lokireddy et al. | RETRACTED: the ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli | |
Aoki et al. | Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3 | |
Stansfield et al. | Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart | |
Zou et al. | AEG-1/MTDH-activated autophagy enhances human malignant glioma susceptibility to TGF-β1-triggered epithelial-mesenchymal transition | |
Alarcon et al. | Cardiac arrhythmias after renal I/R depend on IL-1β | |
Wang et al. | ADSC-derived exosomes attenuate myocardial infarction injury by promoting miR-205-mediated cardiac angiogenesis | |
Yu et al. | By suppressing the expression of anterior pharynx‐defective‐1α and‐1β and inhibiting the aggregation of β‐amyloid protein, magnesium ions inhibit the cognitive decline of amyloid precursor protein/presenilin 1 transgenic mice | |
Huang et al. | Autophagy-related LC3 accumulation interacted directly with LIR containing RIPK1 and RIPK3, stimulating necroptosis in hypoxic cardiomyocytes | |
Zhang et al. | Mzb1 protects against myocardial infarction injury in mice via modulating mitochondrial function and alleviating inflammation | |
Lennikov et al. | Deficiency of CXC chemokine receptor type 5 (CXCR5) gene causes dysfunction of retinal pigment epithelium cells | |
Yan et al. | VIP induces changes in the F-/G-actin ratio of Schlemm's canal endothelium via LRRK2 transcriptional regulation | |
AU2004291809B2 (en) | Method of growing myocardial cells | |
US20210379104A1 (en) | Pharmaceutical composition comprising isolated mitochondria for preventing or treating tendinopathy | |
Yin | Pericyte-derived heme-binding protein 1 promotes angiogenesis and improves erectile function in diabetic mice | |
Qin et al. | Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy | |
CN117771345A (zh) | Wac在制备预防和/或治疗骨质疏松症的药剂中的应用 | |
Bai et al. | The promotion action of AURKA on post-ischemic angiogenesis in diabetes-related limb ischemia | |
Xu et al. | Myosin 1b Participated in the Modulation of Hypoxia/Reoxygenation‐Caused H9c2 Cell Apoptosis and Autophagy | |
Gao et al. | SUMO2-mediated SUMOylation of SH3GLB1 promotes ionizing radiation-induced hypertrophic cardiomyopathy through mitophagy activation | |
Li et al. | Biphasic calcium phosphate recruits Tregs to promote bone regeneration | |
Lyzogubov et al. | Inhibition of new vessel growth in mouse model of laser-induced choroidal neovascularization by adiponectin peptide II | |
Li et al. | MTIM affects retinal ganglion cells through PI3K/AKT signaling pathway. | |
US8729021B2 (en) | PTD-UQCRB fusion polypeptide, and pharmaceutical composition for preventing and treating ischemic diseases, containing same | |
CN111701021B (zh) | Nipa2作为药物靶点在制备治疗2型糖尿病性骨质疏松的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |